INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Rilvegostomig, MYCOPHENOLATE MOFETIL
D702GC00001
Phase 3 small_molecule active
Quick answer
INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Rilvegostomig, MYCOPHENOLATE MOFETIL for Lung Cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active